Patients will have routine access to more cancer drugs as companies have dropped their prices as part of the reformed Cancer Drugs Fund (CDF) process.
NICE is now halfway through the drugs it is considering from the CDF and so far all have been recommended for routine NHS use. Companies have provided discounts and in some cases additional evidence meaning the drugs can be considered cost effective for routine NHS use.
The CDF was established by the Government in 2010 as a temporary solution to help patients access cancer drugs that were not widely available on the NHS. However the Fund quickly exceeded its original £200 million budget.
Read Full Article Here >>